INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Hospital Universitario Lucus Augusti
Lugo, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Lucus Augusti (24)
2024
-
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
eClinicalMedicine, Vol. 71
-
Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry
Haematologica, Vol. 109, Núm. 1, pp. 115-128
-
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort
Lupus Science and Medicine, Vol. 11, Núm. 1
2023
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022)
Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1021-1031
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
-
Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure
Seminars in Arthritis and Rheumatism, Vol. 52
-
RICORS2040: The need for collaborative research in chronic kidney disease
Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387
2021
-
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Leukemia, Vol. 35, Núm. 6, pp. 1571-1585
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
2020
-
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
Experimental Hematology and Oncology
-
Clinical validation of risk scoring systems to predict risk of delayed bleeding after EMR of large colorectal lesions
Gastrointestinal Endoscopy, Vol. 91, Núm. 4, pp. 868-878.e3
-
Corrigendum to “Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study” [Leuk. Res. 92 (March) (2020) 06352] (Leukemia Research (2020) 92, (S0145212620300576), (10.1016/j.leukres.2020.106352))
Leukemia Research
-
Hormonal Dependence and Cancer in Systemic Lupus Erythematosus
Arthritis Care and Research, Vol. 72, Núm. 2, pp. 216-224
-
Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience
Revista Espanola de Cardiologia, Vol. 73, Núm. 12, pp. 994-1002
-
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study
Leukemia Research, Vol. 92
2019
-
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Leukemia Research, Vol. 76, pp. 1-10
-
Association of candidate gene polymorphisms with chronic kidney disease: Results of a case-control analysis in the NEFRONA cohort
Frontiers in Genetics, Vol. 10, Núm. FEB
-
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases
Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089